Serum Institute

Bavarian Nordic will transfer the technology of the current manufacturing process to SII to enable supply for the Indian market, the company said in a statement on Monday

Bavarian Nordic has partnered with the Serum Institute of India to produce its Mpox vaccine for the Indian market and expand global capacity through contract manufacturing

The capital raised through this pledge is expected to support Mankind Pharma's strategic initiatives and growth plans

The announcement was made after market hours. On Wednesday, Mankind Pharma's shares closed at Rs 2,529.80 apiece, down 1.46 per cent on the Bombay Stock Exchange (BSE)

More than 2,500 BSV employees will be joining Mankind

AstraZeneca Covid vaccine row: As of April 30, 2024, over 1.7 billion doses of the Covishield vaccine has been administered in India

Former ICMR scientist Raman Gangakhedkar said the risk is highest after the initial dose, eventually decreasing with subsequent doses

Father says that AstraZeneca's admission of vaccine's rare side effect is 'too late'

Manufactured first in 2021, the AstraZeneca vaccine, known in India as Covishield, has been facing scrutiny over the years, with many countries banning it back in 2021 itself

Ella takes over the presidency from Adar C Poonawalla, who held the post from 2019 to March 2024

IPV has been introduced in UIP as part of Global Polio end-game strategy since November 2015 initially in six states, which was expanded across the country by April 2016

Covid cases in India: On Friday, India recorded 640 fresh Covid-19 infections and the number of active cases now stands at 2,997

Indian billionaire Adar Poonawalla has agreed to pay £138 million for Aberconway House, a 1920s home near Hyde Park, in one of the city's most expensive home sales of the year

India roll-out timelines not known immediately

Serum Institute of Life Sciences will invest an additional USD 150 million in Biocon Biologics as the partners decided to restructure the deal which was inked in 2021, Biocon said on Tuesday. With the fresh capital infusion, Serum's total investment in Biocon Biologics will touch USD 300 million. Biocon Biologics Limited (BBL) and Serum Institute of Life Sciences (SILS) have reached an agreement to withdraw from the original equity structure contemplated under their strategic alliance announced in September, 2021, the Bengaluru-based biotechnology firm said in a statement. As per the new terms of the collaboration, Serum Life Sciences, a part of vaccine major Serum Institute of India, would make an additional equity investment of USD 150 million through the conversion of the USD 150 million loan provided to Biocon Pharma Ltd, a wholly-owned subsidiary of Biocon Ltd, into equity in BBL, it noted. This investment is in addition to the USD 150 million that Serum Institute of Life ...

SILS will now make an additional equity investment of $150 million through the conversion of an earlier loan provided to Biocon Pharma into equity in BBL

In view of rising cases of COVID-19 in various parts of the country, Union Health Minister Mansukh Mandaviya is learnt to have approved the inclusion of Serum Institute's Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday. Covovax is likely to be available on the portal in a few days at a price of Rs 225 per dose plus applicable GST. The move comes after a letter was written by Prakash Kumar Singh, Director, Serum Institute of India (SII) to the Union health ministry on March 27, the sources said. According to an official source, Singh had mentioned in his letter to the ministry that Covovax is a world class vaccine approved by the DCGI, WHO and USFDA and it should be included on the CoWIN portal as a heterologous booster dose for adults. Covovax can be administered to those who have already vaccinated with Covishield or Covaxin. Last month, the COVID-19 Working Group headed by Dr N K Arora had also recommended to the Health Mini

Amid rising coronavirus cases, the Serum Institute of India has written a letter to the Union health ministry seeking the inclusion of its COVID-19 vaccine Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday. The letter was written by Prakash Kumar Singh, Director, Serum Institute of India (SII) on March 27, they said. Last month, COVID-19 Working Group headed by Dr N K Arora had also recommended to the health ministry inclusion of Covovax on the CoWIN portal as a heterologous booster dose for adults who have been vaccinated with two doses of either Covishield or Covaxin. The Drugs Controller General of India (DCGI) had on January 16 approved the market authorisation for Covovax for those who have been administered two doses of either Covishield or Covaxin. Also, Covovax has been approved by the World Health Organisation (WHO) and the US Food and Drug Administration (USFDA). The DCGI had approved Covovax for restricted use in ...

Surge in demand for Covishield led to a huge spike in its revenues and profits

A day after the first indigenously developed Human Papillomavirus vaccine against cervical cancer was launched, Serum Institute of India CEO Adar Poonawalla on Wednesday said the vaccine will be available in small quantity this year and its production will be boosted next year to take care of the needs of the nation. Speaking on the sidelines of an event after presenting the vaccine to Union Health Minister Mansukh Mandaviya, Poonawalla said the vaccine 'CERVAVAC' will be made available through the government programme this year. The vaccine for 9-14-year-old was launched on Tuesday in the presence of Union Home Minister Amit Shah, Poonawalla, and Director of Government and Regulatory Affairs at Serum Institute of India, Prakash K Singh. It will be available at a much lower price than the internationally branded vaccines available in the market, Singh had said earlier. The vaccine will be included in the National Immunisation Programme by mid-2023, government officials had said.